Regarding tau protein expression, the findings indicated minimal variation across treatment groups; nonetheless, the high-dose HUP intervention group significantly decreased the expression of phosphorylated tau at serine 404 (p-tau S404) relative to the AD group (p < 0.05), achieving an effect comparable to that of donepezil. The gene discussed is MAPT; the disease is Alzheimer disease.